An Immunological Comparison of Third Companion in Advanced Drug-Naive HIV-Infected Patients

REFERENCES

• d'Arminio Monforte A, Lepri Cozzi A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 2000;14: 499–507.
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Fath MJ, DeMasi R, et al. An update systematic overview of triple combination therapies in antiretroviral naive HIV infected adults. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infec-tions; February 22–25, 2005; Boston, Massachusetts, USA. Abstract 586.
   Google Scholar
• http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
   Google Scholar
• Gallant JE, Rodriguez AE, Weinberg W, et al. Early non response to tenofovir (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFZ) + ABC and 3TC: ESS 30009 unplanned interim analysis. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Che-motherapy; September 14–17, 2003; Chicago, IL. Abstract Hi 722a.
   Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleo-side regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New Engl J Med. 2004;350:1850–1861.
   PubMed Web of Science ®Google Scholar
• Jemsek J, Hutchereson P, Harper E. Poor virologic re-sponses and early emergence of resistance in treatment naive, HIV infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir TDF. In: Program and abstracts of the 11th Con-ference on Retroviruses and Opportunistic Infections; Feb-ruary 8–11, 2004; San Francisco, CA, USA. Abstract 51.
   Google Scholar
• Kirkland LR, Fisch! MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511–518.
   PubMed Web of Science ®Google Scholar
• Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failure in once-daily regimen of abacavir, lamivudine and tenofovir: the TONUS study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic In-fections; February 8–11, 2004; San Francisco, CA, USA. Abstract 52.
   Google Scholar
• Seaton RA, Fox R, Bodasing N, Peters SE, Gourley Y. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with ad-vanced HIV-1 infection. AIDS. 2003;17: 445–453.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleo-side regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. New Engl J Med. 2004;350:1850–1861.
   PubMed Web of Science ®Google Scholar
• Gulick R. Combination therapy for patients with HIV-1 infec-tion: the use of dual nucleoside analogues with protease inhibitors and other agents. AIDS. 1998;12\(suppl 3):S17–22.
   PubMed Web of Science ®Google Scholar
• Fauci AS. Immunopathogenic mechanisms of HIV infection. Ann Int Med. 1996,124:654–663.
   PubMed Web of Science ®Google Scholar
• Gorochov G, Neumann AU, Parizot C, Li T, Katlama C, Debra P. Down-regulation of CD8+ T cell-expansions in patients with HIV infection receiving highly active combina-tion therapy. Blood. 2001,97:1787–1795.
   PubMed Web of Science ®Google Scholar
• Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolitic function. J Exp Med. 2000;192:63–75.
   PubMed Web of Science ®Google Scholar
• Trabattoni D, Piconi S, Biasin M, et al. Granule-dependent mechanisms of lysis are defective in CD8+ T cells of HIV-infected, antiviral therapy-treated individuals. AIDS. 2004;18:859–869.
   PubMed Web of Science ®Google Scholar
• Clerici M, Stocks NI, Zajac RA, et al. IL-2 production permits detection of antigenic peptide recognition by T helper lym-phocytes from asymptomatic, HIV seropositive individuals. Nature. 1989;339:383–385.
   PubMed Web of Science ®Google Scholar
• DeLisi C, Berzofsky JA. T cell antigenic sites tend to be amphipathic structures. Proc Nat/ Acad Sci (USA). 1985;82:7048–7052.
   PubMed Web of Science ®Google Scholar
• Trabattoni D, Lo Caputo S, Biasin M, et al. Modulation of human immunodeficiency virus (HIV)-specific immune re-sponse by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin Diagn Lab ImmunoL 2002;9(5):1114–1118.
   PubMedGoogle Scholar
• Angel JAB, Kumar A, Parato A, et al. Improvement in cell-mediated immune function, during potent anti-human im-munodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898–904.
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Li TS, et al. Positive effects of com-bined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112–116.
   PubMed Web of Science ®Google Scholar
• Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations of the immune response of HIV-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis.1996;173:321–329.
   PubMed Web of Science ®Google Scholar
• Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS. 1998;12:1833–1844.
   PubMed Web of Science ®Google Scholar
• Weiss L, Burgard M, Cahen YD, et al. Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy. HIV Med. 2002;3:12–20.
   PubMedGoogle Scholar
• Barreiro P, Soriano V, Cases E, Gonzalez-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS. 2002;25:245–249.
   Google Scholar
• Benito JM, Lopez M, Martin JC, et al. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors. AIDS Res Hum Retrovir. 2002;18:1379–1388.
   PubMed Web of Science ®Google Scholar
• Piconi S, Trabattoni D, Fusi ML, et al. Effect of two different combinations of antiretrovirals (AZT+ddl and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection. Antiviral Res. 2000;46:171–179.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). AIDS. 2002;16:1554–1556.
   PubMed Web of Science ®Google Scholar
• Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. JAIDS. 2004;35: 22–32.
   Google Scholar
• Pulido F, Arribas JR, Miro JM, et al. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). JAIDS. 2004;35:343–350.
   Google Scholar
• Gathe JC Jr, Lye P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529–1537.
   PubMed Web of Science ®Google Scholar
• Rosenblatt HM, Stanley KE, Song LY, et al. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. J Infect Dis. 2005;192:445–455.
   PubMed Web of Science ®Google Scholar
• Lange CG, Lederman MM, Madero JS, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. JAIDS. 200230: 33–40.
   Google Scholar
• Saag MS. The impact of highly active antiretroviral therapy on HIV-specific immune function. AIDS. 200115:S4–S10.
   Google Scholar
• Lederman MM. Immune restoration and CD4+T-cell func-tion with antiretroviral therapies. AIDS. 200115:S11–S15.
   Google Scholar
• Lederman MM, Valdez H. Immune restoration with antiretroviral therapies - implications for clinical manage-ment. JAMA. 2000;284:223–228.
   PubMed Web of Science ®Google Scholar
• Cooper DA. Immunological effects of antiretroviral therapy. Antiviral Ther. 1998;3:19–23.
   PubMed Web of Science ®Google Scholar
• Shaefer MS. Abacavir/Lamivudine/Zidovudine continues to be a valid and useful antiretroviral regimen. Annals Pharmacother. 2004;38:1314–1316.
   PubMed Web of Science ®Google Scholar
• Kessler HA. Triple-nucleoside analog antiretroviral therapy: Is there still a role in clinical practice? A review. MedGenMed. 2005;7:70.
   PubMedGoogle Scholar